Cited by 24Growth Hormone and Insulin-like Growth FactorsPituitary Gland Disorders and TreatmentsTraumatic Brain Injury and Neurovascular Disturbances

Alterations of the GH/IGF-I Axis and Gut Microbiome after Traumatic Brain Injury: A New Clinical Syndrome?

Open access
Yuen, Kevin C J, Masel, Brent E, Reifschneider, Kent L, Sheffield-Moore, Melinda, Urban, Randall J, Pyles, Richard B·2020·The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: Pituitary dysfunction with abnormal growth hormone (GH) secretion and neurocognitive deficits are common consequences of traumatic brain injury (TBI). Recognizing the comorbidity of these symptoms is of clinical importance; however, efficacious treatment is currently lacking. Evidence Acquisition: A review of studies in PubMed published between January 1980 to March 2020 and ongoing clinical trials was conducted using the search terms “growth hormone,” “traumatic brain injury,” and “gut microbiome.” Evidence Synthesis: Increasing evidence has implicated the effects of TBI in promoting an interplay of ischemia, cytotoxicity, and inflammation that renders a subset of patients to develop postinjury hypopituitarism, severe fatigue, and impaired cognition and behavioral processes. Recent data have suggested an association between abnormal GH secretion and altered gut microbiome in TBI patients, thus prompting the description of a hypothesized new clinical syndrome called “brain injury associated fatigue and altered cognition.” Notably, these patients demonstrate distinct characteristics from those with GH deficiency from other non-TBI causes in that their symptom complex improves significantly with recombinant human GH treatment, but does not reverse the underlying mechanistic cause as symptoms typically recur upon treatment cessation. Conclusion: The reviewed data describe the importance of alterations of the GH/insulin-like growth factor I axis and gut microbiome after brain injury and its influence in promoting neurocognitive and behavioral deficits in a bidirectional relationship, and highlight a new clinical syndrome that may exist in a subset of TBI patients in whom recombinant human GH therapy could significantly improve symptomatology. More studies are needed to further characterize this clinical syndrome.

Integrity signals

Registry

Crossref · 10.1210/clinem/dgaa398

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies indicate that the majority of children diagnosed with TBI-related GHD show onset of symptoms between 6 months and 2 years post-injury, with some cases taking longer.

    “Studies indicate that the majority of children diagnosed with TBI-related GHD show onset of symptoms between 6 months and 2 years post-injury, with some cases taking longer to manifest [24,25,26,27].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yuen, K. C. J., Masel, B. E., Reifschneider, K. L., Sheffield-Moore, M., Urban, R. J., & Pyles, R. B.
Affiliations
  • Barrow Neurological Institute (US)
  • Centre for Neuro Skills, Bakersfield, California
  • Children's Specialty Group (US)
  • Department of Health and Kinesiology, Texas A & M University, College Station, Texas
  • The University of Texas Medical Branch at Galveston (US)
Corresponding author
Yuen, Kevin C J
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2020-06-25
Volume
105
Issue
9
Pages
e3054-e3064
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3037240533
Cited by
24
References
110
Citations by year
2026: 4 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 5
FWCI
0.50
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Neurology › Traumatic Brain Injury and Neurovascular Disturbances
Keywords
traumatic brain injury, growth hormone, insulin-like growth factor I, gut microbiota, hypopituitarism, recombinant human growth hormone therapy, neurocognitive impairment, fatigue, pituitary dysfunction, inflammation
MeSH terms
Gastrointestinal Microbiome, Brain Injuries, Traumatic, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Syndrome, Signal Transduction, Treatment Outcome, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review